Literature DB >> 19639303

Extended naltrexone and broad spectrum treatment or motivational enhancement therapy.

Richard Longabaugh1, Philip W Wirtz, Suzy Bird Gulliver, Dena Davidson.   

Abstract

BACKGROUND: Randomized clinical trials on the effectiveness of naltrexone (NTX) in the treatment of alcohol dependence have produced conflicting results. One possible explanation for these discrepancies may lie in the various psychosocial treatments for which NTX is an adjunct. The goal of this study was to examine the interplay between psychosocial treatment and duration of NTX.
METHODS: One hundred and seventy-four alcohol-dependent outpatients participated in a double-blind trial where they were randomly assigned to 12 vs. 24 weeks NTX duration and to one of two psychosocial treatments: motivational enhancement therapy (MET) and broad spectrum treatment (BST), a cognitive behavioral therapy tailored to the patient's specific needs. After an initial 12-week period of NTX and psychosocial treatment, half of each psychotherapy condition was assigned to continue NTX for an additional 12 weeks while the other half was assigned to placebo. Patient drinking outcomes were measured for the year following treatment completion. It was hypothesized that the combination of extended duration of NTX and the moderate intensity of BST would be predictive of longer time to a first heavy drinking day than any of the three alternative combinations: MET with short or extended NTX administration or BST with short NTX administration.
RESULTS: The median time to first drink and time to first heavy drinking day were found to be significantly longer for patients who received BST and extended NTX than for patients in the other three groups.
CONCLUSIONS: These results may suggest that the kind of psychosocial treatment delivered in combination with duration of NTX administration may partially explain the inconsistent findings regarding the efficacy of NTX in the treatment of alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639303     DOI: 10.1007/s00213-009-1615-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

Review 1.  Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.

Authors:  William R Miller; Paula L Wilbourne
Journal:  Addiction       Date:  2002-03       Impact factor: 6.526

2.  A comparison sample validation of "your workplace": an instrument to measure perceived alcohol support and consequences from the work environment.

Authors:  C Rice; R Longabaugh; R L Stout
Journal:  Addict Behav       Date:  1997 Sep-Oct       Impact factor: 3.913

3.  Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.

Authors:  Raymond F Anton; Darlene H Moak; Patricia Latham; L Randolph Waid; Hugh Myrick; Konstantin Voronin; Angelica Thevos; Wei Wang; Robert Woolson
Journal:  J Clin Psychopharmacol       Date:  2005-08       Impact factor: 3.153

4.  Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.

Authors:  Markus Gastpar; Udo Bonnet; Jobst Böning; Karl Mann; Lutz G Schmidt; Michael Soyka; Tilman Wetterling; Volker Kielstein; Dominic Labriola; Robert Croop
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

5.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

6.  Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Authors:  P M Monti; D J Rohsenow; R M Swift; S B Gulliver; S M Colby; T I Mueller; R A Brown; A Gordon; D B Abrams; R S Niaura; M K Asher
Journal:  Alcohol Clin Exp Res       Date:  2001-11       Impact factor: 3.455

7.  Naltrexone-induced alterations in human ethanol intoxication.

Authors:  R M Swift; W Whelihan; O Kuznetsov; G Buongiorno; H Hsuing
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

8.  Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

Authors:  Stephanie S O'Malley; Bruce J Rounsaville; Conor Farren; Kee Namkoong; Ran Wu; Jane Robinson; Patrick G O'Connor
Journal:  Arch Intern Med       Date:  2003-07-28

9.  A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.

Authors:  David W Oslin; Kevin G Lynch; Helen M Pettinati; Kyle M Kampman; Peter Gariti; Lois Gelfand; Thomas Ten Have; Shoshana Wortman; William Dundon; Charles Dackis; Joseph R Volpicelli; Charles P O'Brien
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

10.  Naltrexone in the treatment of alcoholism: predicting response to naltrexone.

Authors:  J R Volpicelli; K L Clay; N T Watson; C P O'Brien
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

View more
  6 in total

Review 1.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 2.  Medical treatment of alcohol dependence: a systematic review.

Authors:  Peter M Miller; Sarah W Book; Scott H Stewart
Journal:  Int J Psychiatry Med       Date:  2011       Impact factor: 1.210

3.  How do providers serving American Indians and Alaska Natives with substance abuse problems define evidence-based treatment?

Authors:  Laurie A Moore; Gregory A Aarons; Jordan H Davis; Douglas K Novins
Journal:  Psychol Serv       Date:  2015-05

Review 4.  Pharmacotherapeutic approach to the treatment of addiction: persistent challenges.

Authors:  Daniel S Zahm
Journal:  Mo Med       Date:  2010 Jul-Aug

Review 5.  Integrated treatment of substance use and psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley
Journal:  Soc Work Public Health       Date:  2013

Review 6.  Motivational interviewing for substance abuse.

Authors:  Geir Smedslund; Rigmor C Berg; Karianne T Hammerstrøm; Asbjørn Steiro; Kari A Leiknes; Helene M Dahl; Kjetil Karlsen
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.